May 11, 2017
Our new issue of Px Wire offers an advocate’s guide to some new types of biomedical prevention trial designs.
Next-generation PrEP products include long-acting injectable ARVs (which are also being tested for treatment in people living with HIV). How do you find out if injectable PrEP is better, or as least as good as, daily oral PrEP? The new trial designs hold possible answers.
In this info-rich Px Wire, you’ll find a handy summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
